Bluebird Bio Inc., of Cambridge, Mass., said the NIH Recombinant DNA Advisory Committee (RAC) completed its public review of the HGB-208 pediatric study protocol for Bluebird's LentiglobinBB305 product candidate in beta-thalassemia major and recommended the delay of the study in the U.S. for one to two years.